Mikkael Aaron Sekeres

Mikkael Aaron Sekeres's AcademicInfluence.com Rankings

Philosophy

#5908

World Rank

#8841

Historical Rank

Logic

#3119

World Rank

#4231

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Mikkael Aaron Sekeres's Degrees

Doctorate Medicine University of Pennsylvania
Masters Clinical Research University of Pennsylvania

Why Is Mikkael Aaron Sekeres Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mikkael Aaron Sekeres's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised international prognostic scoring system for myelodysplastic syndromes. (2012) (2285)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. (2015) (1351)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017) (1021)
Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML (2018) (912)
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. (2009) (387)
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. (2012) (378)
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. (2012) (347)
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. (2008) (324)
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. (2011) (324)
Dynamics of clonal evolution in myelodysplastic syndromes (2016) (311)
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. (2008) (302)
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. (2015) (299)
Acute myeloid leukemia. (2012) (280)
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms (2014) (270)
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. (2008) (239)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) (238)
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. (2017) (226)
Somatic SETBP1 mutations in myeloid malignancies (2013) (225)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. (2019) (221)
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts (2012) (218)
The incidence and impact of thrombocytopenia in myelodysplastic syndromes (2007) (212)
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. (2011) (198)
The epidemiology of myelodysplastic syndromes. (2010) (196)
Genetic alterations of the cohesin complex genes in myeloid malignancies. (2014) (194)
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. (2009) (193)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes (2021) (192)
Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome (2004) (192)
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. (2006) (191)
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies (2010) (185)
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. (2009) (179)
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. (2012) (179)
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (2010) (169)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. (2017) (166)
Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. (2013) (160)
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia (2014) (142)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. (2016) (134)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. (2017) (130)
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. (2012) (125)
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies (2013) (125)
Time-dependent changes in mortality and transformation risk in MDS. (2016) (120)
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes (2016) (119)
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. (2009) (116)
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study (2012) (114)
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. (2010) (114)
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. (2012) (110)
Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality (2017) (110)
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. (2013) (109)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) (2015) (108)
SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. (2011) (108)
Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia (2017) (107)
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub (2020) (107)
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies (2015) (106)
Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy (2013) (106)
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. (2008) (105)
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. (2004) (105)
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. (2012) (104)
Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis (2012) (102)
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion (2013) (101)
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. (2018) (99)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. (2018) (98)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS (2020) (98)
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia (2011) (97)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (2015) (95)
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. (2010) (91)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results (2018) (90)
Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes (2017) (85)
How we treat higher-risk myelodysplastic syndromes. (2014) (85)
Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium (2015) (85)
Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia (2013) (84)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. (2018) (83)
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. (2020) (82)
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS (2013) (82)
Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome (2012) (81)
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia (2013) (81)
Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes (2008) (80)
Genomic determinants of chronic myelomonocytic leukemia (2017) (78)
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) (2016) (76)
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. (2019) (74)
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. (2017) (73)
CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS (2015) (73)
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial (2015) (72)
Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. (2011) (70)
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. (2019) (69)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. (2011) (69)
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors (2018) (69)
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. (2005) (69)
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) (2019) (69)
FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). (2010) (68)
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). (2020) (68)
Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes (2007) (68)
An assessment of the usefulness of the Duke criteria for diagnosing active infective endocarditis. (1997) (67)
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (2018) (64)
p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia (2011) (64)
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. (2017) (63)
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes (2011) (63)
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (2012) (62)
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. (2015) (62)
Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation (2016) (60)
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides (2016) (60)
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL) (2018) (60)
Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. (1998) (60)
Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2018) (57)
Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). (2010) (56)
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. (2020) (56)
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts (2020) (55)
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions (2018) (53)
Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary Bypass (2002) (53)
Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies (2012) (53)
Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron (2014) (52)
Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. (2007) (51)
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. (2013) (51)
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (2021) (51)
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes (2017) (50)
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. (2015) (50)
Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis (2014) (50)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. (2011) (49)
The challenge of acute myeloid leukemia in older patients (2002) (49)
A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (2018) (49)
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher‐risk myelodysplastic syndromes (2011) (48)
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. (2012) (48)
Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives (2008) (48)
SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) (2016) (48)
Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS) (2016) (47)
Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment. (2007) (47)
Origins of myelodysplastic syndromes after aplastic anemia. (2017) (46)
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts (2017) (46)
Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department. (2015) (46)
Myelodysplastic syndromes: A practical approach to diagnosis and treatment (2010) (43)
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium (2017) (43)
Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117 (2014) (42)
Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. (1998) (42)
Consequences of mutant TET2 on clonality and subclonal hierarchy (2018) (42)
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. (2020) (41)
Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. (2013) (41)
The impact of a physician awareness group and the first year of training on hematology-oncology fellows. (2003) (41)
Recurrent genetic defects on chromosome 7q in myeloid neoplasms (2014) (41)
Severe megaloblastic anemia: Vitamin deficiency and other causes (2020) (40)
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. (2010) (39)
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes (2019) (39)
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure (2016) (38)
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy (2017) (38)
Recurrent genetic defects on chromosome 5q in myeloid neoplasms (2016) (38)
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS (2020) (37)
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence (2019) (37)
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. (2019) (37)
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study (2020) (37)
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome (2021) (36)
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. (2016) (36)
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia (2007) (35)
Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. (2008) (35)
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction (2014) (35)
Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study (2012) (34)
Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. (2018) (34)
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. (2018) (34)
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. (2018) (34)
Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. (2012) (33)
Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS (2007) (33)
Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight (2013) (33)
High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. (2007) (33)
Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS (2011) (33)
Hemochromatosis‐associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts (2007) (33)
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia (2014) (33)
Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes (2014) (33)
Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit (2008) (32)
Febrile Neutropenia in Hematologic Malignancies (2013) (32)
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA® registry (2015) (32)
A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials (2017) (32)
The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine (2014) (32)
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 (2018) (31)
Complex Landscape of Alternative Splicing in Myeloid Neoplasms (2020) (31)
Elacytarabine has single‐agent activity in patients  with advanced acute myeloid leukaemia (2012) (30)
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia (2011) (29)
Absolute lymphocyte count at day 28 independently predicts event‐free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia (2012) (29)
Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine (2018) (29)
Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. (2008) (29)
14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) (2011) (29)
A Decision analysis to determine the appropriate treatment for low‐risk myelodysplastic syndromes (2007) (28)
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome (2013) (27)
Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R (2018) (27)
Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better? (2015) (27)
Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms (2016) (27)
Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA) (2019) (27)
Development of a Modified Surveillance Definition of Central Line–Associated Bloodstream Infections for Patients with Hematologic Malignancies (2012) (27)
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion (2014) (27)
The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine (2019) (27)
A phase 1 study of AMG 900, an orally administered pan‐aurora kinase inhibitor, in adult patients with acute myeloid leukemia (2017) (26)
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia (2019) (26)
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. (2019) (26)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. (2021) (26)
Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome (2019) (26)
Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma (2007) (26)
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide (2012) (26)
Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study (2017) (26)
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. (2016) (25)
Combination strategies in myelodysplastic syndromes (2012) (25)
Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study (2011) (25)
Predictive factors for latency period and a prognostic model for survival in patients with therapy‐related acute myeloid leukemia (2014) (25)
Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence (2011) (25)
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series (2018) (25)
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. (2019) (24)
The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. (2014) (24)
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS) (2019) (24)
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy (2020) (24)
More is better: combination therapies for myelodysplastic syndromes. (2015) (24)
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide (2014) (24)
Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) (2008) (24)
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. (2018) (23)
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q) (2014) (23)
PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin (2014) (23)
Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course (2016) (23)
Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes (2015) (23)
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? (2015) (23)
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts (2014) (23)
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF) (2012) (23)
Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. (2018) (23)
Efficacy of rabbit antithymocyte globulin in severe aplastic anemia (2011) (23)
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) (2012) (22)
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)* (2017) (22)
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia (2020) (22)
Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients (2010) (22)
Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes (2019) (22)
PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED >= 65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR INTENSIVE THERAPY (2016) (22)
Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models (2016) (22)
BRCC3 mutations in myeloid neoplasms (2015) (21)
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States (2017) (21)
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. (2014) (21)
Thalidomide use and digital gangrene. (2006) (21)
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (2019) (21)
The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes (2015) (20)
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study (2017) (20)
The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies (2017) (20)
Molecular features of early onset adult myelodysplastic syndrome (2017) (20)
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes (2021) (20)
ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. (2014) (20)
The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? (2013) (19)
The avastin story. (2011) (19)
Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs) (2014) (19)
Distinct clinical and biological implications of CUX1 in myeloid neoplasms. (2019) (19)
Epidemiology and risk factors for infections in myelodysplastic syndromes (2013) (19)
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine (2014) (19)
Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes (2014) (18)
Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy (2015) (18)
Subclonal STAT3 mutations solidify clonal dominance. (2019) (18)
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. (2018) (18)
Genomics of therapy-related myeloid neoplasms (2020) (17)
Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine (2015) (17)
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. (2010) (17)
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts (2015) (16)
Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia (2010) (16)
Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes (2014) (16)
Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia. (2021) (16)
The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML) (2020) (16)
Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML) (2010) (16)
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin (2009) (16)
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) (2021) (15)
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. (2010) (15)
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care (2017) (15)
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium (2020) (15)
Evaluation of cell-free DNA approaches for multi-cancer early detection. (2022) (15)
Two patients with sarcoma. Case 1. Synovial cell sarcoma of the lung. (2000) (15)
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. (2017) (15)
Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (2017) (15)
Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #110 (2014) (15)
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. (2018) (15)
A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS). (2009) (15)
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. (2017) (15)
New data with arsenic trioxide in leukemias and myelodysplastic syndromes. (2007) (15)
Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia (2007) (14)
Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML (2017) (14)
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia (2012) (14)
Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites (2015) (14)
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey* (2018) (14)
Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML). (2018) (14)
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 (2020) (14)
OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia (2010) (14)
A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (2019) (14)
Rethinking clinical trial endpoints in myelodysplastic syndromes (2019) (14)
BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes (2016) (14)
Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges. (2013) (13)
Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations (2016) (13)
SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype (2013) (13)
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777). (2020) (13)
Failure to Detect Mutations in U2AF1 due to Changes in the GRCh38 Reference Sequence (2021) (13)
Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients withTP53mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (2018) (13)
Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression. (2009) (13)
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. (2009) (13)
A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence (2019) (12)
Long‐Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population (2017) (12)
Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles (2017) (12)
The complexity of interpreting genomic data in patients with acute myeloid leukemia (2016) (12)
Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS) (2009) (12)
Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q). (2009) (12)
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy (2020) (12)
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy (2017) (12)
Cancer research in the United States: A critical review of current status and proposal for alternative models (2018) (12)
Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia (2019) (12)
Established and novel agents for myelodysplastic syndromes. (2014) (11)
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis (2018) (11)
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial (2014) (11)
New drugs in AML: uses and abuses (2018) (11)
The myelodysplastic syndromes (2007) (11)
14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION (2015) (11)
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML (2022) (11)
Older adults with acute myeloid leukemia (2002) (11)
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study (2016) (11)
Immunomodulation in myelodysplastic syndromes. (2006) (11)
White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia (2007) (11)
Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10) (2014) (11)
Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics (2012) (10)
Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years. (2019) (10)
A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia (2018) (10)
Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. (2016) (10)
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. (2021) (10)
TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS) (2016) (10)
Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms (2018) (10)
The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes (2008) (10)
Lenalidomide in MDS: 4th time's a charm. (2011) (10)
A drug's life: the pathway to drug approval. (2013) (10)
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia (2021) (10)
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL) (2011) (10)
Race and intensity of post-remission therapy in acute myeloid leukemia. (2011) (10)
The role of post-remission chemotherapy for older patients with acute myelogenous leukemia (2006) (9)
Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia. (2008) (9)
Arsenic trioxide as a treatment for myelodysplastic syndrome (2006) (9)
Evolving strategies in the treatment of MDS and AML. (2009) (9)
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy (2015) (9)
Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse? (2017) (9)
Are we nearer to curing patients with MDS? (2010) (9)
A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML. (2009) (9)
Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium (2015) (9)
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. (2022) (9)
Clinical Malignant Hematology (2007) (9)
A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS) (2015) (9)
Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality (2015) (9)
Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. (2015) (9)
An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2015) (9)
Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study (2015) (9)
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions (2018) (9)
Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure (2017) (9)
The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. (2008) (9)
Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) (2015) (9)
TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee (2014) (9)
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. (2008) (8)
Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program (2021) (8)
Distinctive and common features of moderate aplastic anaemia (2020) (8)
Novel invariant features of Good syndrome (2021) (8)
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. (2022) (8)
Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic (2013) (8)
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. (2022) (8)
Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) (2011) (8)
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. (2021) (8)
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS). (2009) (8)
Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954) (2021) (8)
Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients (2013) (8)
Azacitidine in Myelodysplastic Syndromes (2012) (8)
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) (2017) (8)
Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies (2012) (8)
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605) (2010) (8)
The euphoria of hypomethylating agents in MDS and AML: is it justified? (2013) (8)
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. (2020) (8)
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions (2020) (8)
De Novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone (2012) (8)
The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort (2016) (8)
Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (2011) (8)
Time from Diagnosis to Treatment Initiation Predicts Survival in Acute Myeloid Leukemia (AML). (2007) (8)
A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN (2012) (7)
Timed sequential induction chemotherapy and risk‐adapted postremission therapy for acute myelogenous leukemia (2008) (7)
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. (2017) (7)
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. (2017) (7)
Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection (2017) (7)
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. (2020) (7)
1040TiPQuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML) (2017) (7)
Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. (2017) (7)
Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA). (2019) (7)
A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome. (2005) (7)
Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. (2021) (7)
Lenalidomide in del 5q MDS: responses and side effects revisited. (2011) (7)
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions (2018) (7)
Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies (2018) (7)
Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure (2019) (7)
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. (2018) (7)
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy (2017) (7)
CliniCal eValuation and treatment of aml (2009) (7)
How to manage lower-risk myelodysplastic syndromes (2012) (7)
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes (2019) (7)
Treatment of MDS: something old, something new, something borrowed... (2009) (7)
Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial (2019) (7)
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes (2021) (7)
Bone marrow transplantation (BMT) in myelodysplastic syndromes: to BMT or not to BMT--that is the question. (2013) (7)
Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes (2014) (7)
The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort (2017) (7)
A Randomized Controlled Trial of Spiritually-Focused Meditation In Patients Newly Diagnosed with Acute Leukemia. (2010) (7)
Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis (2013) (6)
Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study (2015) (6)
Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS). (2006) (6)
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation (2020) (6)
Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia. (2015) (6)
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study (2020) (6)
Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia (2008) (6)
Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study, (2011) (6)
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy (2016) (6)
Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs) (2015) (6)
C027 Cytopenias correlate with response to lenalidomide in del 5q MDS patients (2007) (6)
Managing patients with low-risk MDS. (2006) (6)
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes (2020) (6)
Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee. (2018) (6)
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS (2022) (6)
Novel Therapies in Acute Myeloid Leukemia. (2019) (6)
Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response (2015) (6)
Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study (2020) (6)
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial (2021) (6)
A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse (2009) (6)
GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies (2016) (6)
Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes (2013) (6)
Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS). (2007) (6)
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms (2019) (5)
A case of mistaken identity: When lupus masquerades as primary myelofibrosis (2013) (5)
Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study (2016) (5)
The NEDD 8-Activating Enzyme Inhibitor MLN 4924 Disrupts Nucleotide Metabolism and Augments the Ef fi cacy of Cytarabine (2014) (5)
Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia (2022) (5)
Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events (2018) (5)
The Molecular and Cytokine Profile of Triple-Negative (JAK2 V617F, JAK2 exon 12, MPL negative) Myelofibrosis, a Myeloproliferative Neoplasm with Distinct Clinico-Pathologic Characteristics (2012) (5)
Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia. (2018) (5)
Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia (2020) (5)
Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes (2018) (5)
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment (2017) (5)
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response (2018) (5)
U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts (2016) (5)
Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival (2016) (5)
Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials (2016) (5)
Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best (2016) (5)
A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML) (2011) (5)
Improving Prognostic Modeling in Myelodysplastic Syndromes (2016) (5)
Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms (2015) (5)
The Revised International Prognostic Scoring System Molecular (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS) (2015) (5)
On the Edge of Life, I: Assessment of, Reaction to, and Management of the Terminally Ill Recorded in an Intensive Care Unit Journal. (2002) (5)
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial (2021) (5)
A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium (2016) (5)
Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes (2011) (5)
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial (2021) (5)
Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry (2010) (5)
Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2 (2010) (5)
Establishment of Myelodysplastic Syndrome-Specific Methylome: Implications for the Pathogenesis of Clonal Evolution and Association with Survival (2008) (5)
Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001. (2014) (5)
Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia (2019) (4)
Leukemia evolving from paroxysmal nocturnal hemoglobinuria (2019) (4)
Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia Short title: Genetic alterations in myelodysplasia with HCT (2017) (4)
Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub (2020) (4)
Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy (2010) (4)
Preliminary Results from a Phase I Study of Revlimid® (Lenalidomide) in Combination with Vidaza® (Azacitidine) in Patients with Advanced Myelodysplastic Syndromes (MDS). (2007) (4)
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes (2022) (4)
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey (2020) (4)
Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q) (2013) (4)
Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). (2021) (4)
Preliminary Results of Fixed-Dose Oral Clofarabine (CLO) In Patients Who Have Failed Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes (MDS) (2010) (4)
Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative. (2013) (4)
Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS (2015) (4)
Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial (2014) (4)
Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes (2020) (4)
Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2. (2013) (4)
PHF6 Somatic Mutations and Their Functional Role in the Pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2016) (4)
P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis (2013) (4)
Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease (2014) (4)
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes (2022) (4)
Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study (2013) (4)
NGS-Based Copy Number Analysis in 1,185 Patients with Myeloid Neoplasms (2016) (4)
What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)? (2018) (4)
Perceptions of Disease State, Treatment Expectations, and Prognosis Among Patients with Myelodysplastic Syndromes. (2009) (4)
Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q) (2015) (4)
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? (2021) (4)
P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM (2013) (4)
Myelodysplastic syndromes: more prevalent than we know. (2008) (4)
Making a molecular molehill out of a mountain (2011) (4)
Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS) (2017) (4)
Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial. (2019) (4)
Development Paths for New Drugs with Large Treatment Effects Seen Early (2011) (4)
Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. (2015) (4)
Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction (2011) (4)
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group (2019) (4)
Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study) (2010) (4)
In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations (2014) (4)
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good? (2005) (4)
The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia (2020) (4)
The Degree and Effect Of Weight Loss In Acute Myeloid Leukemia Patients Receiving Induction and Post-Remission Chemotherapy (2013) (4)
Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage (2016) (3)
Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations (2015) (3)
Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA) (2014) (3)
Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents (2015) (3)
Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib (2014) (3)
Germline SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes (2017) (3)
Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence. (2020) (3)
Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality (2008) (3)
A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes (2020) (3)
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good? (2006) (3)
The revolution of myelodysplastic syndromes (2011) (3)
TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia (2019) (3)
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q) (2018) (3)
Clinical “MUTATOME” Of Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leukemia (2013) (3)
Efficacy of Rabbit Anti-Thymocyte Globulin (ATG) Compared to Horse ATG In Severe Aplastic Anemia (2010) (3)
Molecular Predictors Of Response To Lenalidomide In Myeloid Malignancies (2013) (3)
A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia (2012) (3)
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. (2020) (3)
What’s All the Fuss About? Facts and Figures About Bone Marrow Failure and Conditions (2012) (3)
Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium (2016) (3)
Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry (2016) (3)
Myelodysplastic syndromes: it is all in the genes. (2012) (3)
The race for survival in myelodysplastic syndromes (2013) (3)
Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group (2017) (3)
Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine (2011) (3)
Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (2010) (3)
Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q) (2010) (3)
Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere (2014) (3)
Evaluation of noncytotoxic DNMT 1-depleting therapy in patients with myelodysplastic syndromes (2019) (3)
Non-transplant therapy for older adults with acute myeloid leukemia. (2006) (3)
Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2016) (3)
Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia (2015) (3)
Ivosidenib (AG‐120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study: AML‐221 (2018) (3)
Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age (2013) (3)
A Prognostic Scoring System for Patients ≤ 60 Years of Age with Acute Lymphocytic Leukemia in First Relapse. (2008) (3)
Presence of JAK2 Mutations in MDS/MPD-u WHO Classified Patients and Not Other Forms of MDS Suggests Their Derivation from Classical Myeloproliferative Syndrome. (2005) (3)
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. (2023) (3)
Blood consult: treating del(5q) myelodysplastic syndromes. (2012) (3)
Myelodysplastic syndromes spatial clusters in disease etiology and outcome (2016) (3)
Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA) (2011) (3)
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2018) (3)
Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS (2020) (3)
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). (2022) (3)
Alternative treatments for myelodysplastic syndromes. (2005) (3)
PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML (2015) (3)
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (2022) (3)
Baseline characteristics and predictors of outcome in patients with myelodysplastic syndromes living in Western Pennsylvania (2011) (3)
The graceful exit or reluctant demise of the older adult with acute myeloid leukemia (2015) (3)
Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival (2022) (3)
Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC) (2015) (3)
My AML cytogenetics classification scheme is better than yours. (2012) (3)
Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML. (2012) (3)
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. (2020) (3)
Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial (2019) (3)
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. (2020) (3)
Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI) (2019) (3)
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS) (2021) (3)
Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration (2010) (3)
An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies (2014) (2)
112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS) (2015) (2)
Denial's Many Faces. (2018) (2)
The Impact of Different TP53 Mutations on Outcome in Patients with Myelodysplastic Syndromes (MDS) (2015) (2)
High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations (2017) (2)
Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy (2015) (2)
LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes (2018) (2)
Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al. (2018) (2)
Romiplostim in Low/INT-1-Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Results from a Randomized, Double-Blind, Placebo-Controlled Study (2017) (2)
Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction? (2019) (2)
Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement (2010) (2)
Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia (2019) (2)
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial (2022) (2)
Analysis of Immunogenetic Factors in Myelodysplastic Syndromes (MDS) Reveals Potential Pathogenic Role Cytokine Genotypes Such as TGF-β. (2007) (2)
Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort (2018) (2)
Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes (2016) (2)
The baby whisperer. (2011) (2)
Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study (2020) (2)
Chemotherapy-Related Amenorrhea (CRA) among Premenopausal Patients Treated for Acute Leukemia. (2006) (2)
Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response. (2006) (2)
Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study (2018) (2)
Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts (2012) (2)
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study (2018) (2)
DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations (2014) (2)
p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study (2014) (2)
IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment. (2021) (2)
Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes (2022) (2)
FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults (2019) (2)
Albumin as a prognostic marker in myelodysplastic syndromes: still relevant after all these years (2015) (2)
Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders (2013) (2)
A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia (2020) (2)
Influence of Killer Immunoglobulin-like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. (2021) (2)
Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis (2015) (2)
Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) (2015) (2)
Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy (2014) (2)
215 Update of open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS) (2011) (2)
The Transplant. (2021) (2)
Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (2010) (2)
On the Edge of Life, II: House Officer Struggles Recorded in an Intensive Care Unit Journal. (2002) (2)
Impact of TET2 mutations on responsiveness to demethylating agents in MDS (2010) (2)
Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy (2016) (2)
Comprehensive Identification Of Germline Alterations In Telomerase Complex Genes By Whole Exome Sequencing Of MDS and Related Myeloid Neoplasms (2013) (2)
Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Interim results after 27/28 weeks. (2006) (2)
Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing (2015) (2)
Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion (2019) (2)
A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) (2017) (2)
A Decision Analysis To Determine the Appropriate Treatment for Low-Risk Myelodysplastic Syndromes. (2005) (2)
Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets (2019) (2)
Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). (2012) (2)
Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation (2012) (2)
SNP Karyotyping in Myelodysplastic Syndromes (MDS) Reveals the Presence of Cryptic Karyotypic Abnormalities, Including Uniparental Disomy, and Has Important Prognostic Implications. (2006) (2)
Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality (2013) (2)
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. (2022) (2)
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey (2018) (2)
Long Day's Journey Into Night for Lower-Risk Myelodysplastic Syndromes. (2016) (2)
Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) (2019) (2)
Textbook of Uncommon Cancer: Fourth Edition (2012) (2)
Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome (2016) (2)
Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA). (2020) (2)
Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years. (2007) (2)
Very superstitious. (2012) (2)
P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS (2007) (2)
The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. (2019) (2)
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes (2019) (2)
Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone (2019) (2)
Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better? (2015) (2)
A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML). (2015) (2)
Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag (2016) (2)
Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression (2014) (2)
Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies (2017) (2)
Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy (2015) (2)
Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) (2015) (2)
A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML. (2008) (2)
Lowering the boom on lower-risk myelodysplastic syndromes. (2019) (2)
Defining Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome. (2012) (2)
Analysis of Clonal Hierarchy Shows That Other Ancestral Events May Precede Evolution of Del(5q) in Myeloid Neoplasms (2014) (2)
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (2021) (2)
Development of a Prognostic Scoring System for Secondary Acute Myeloid Leukemia (sAML) Arising from Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML). (2008) (2)
Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure (2016) (2)
Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts (2013) (2)
Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Registry (2020) (2)
A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). (2011) (2)
Cigarette Smoking Significantly Increases the Risk of Invasive Fungal Disease (IFD) in Acute Myeloid Leukemia (AML) Patients Undergoing Induction Chemotherapy (2011) (2)
Pathogenic Relevance of Germ Line TET2 Alterations (2016) (2)
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia (2022) (1)
A hallmark moment. (2010) (1)
Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype (2014) (1)
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial (2023) (1)
Mutational Landscape of Therapy‐Related Myeloid Neoplasms: MDS‐304 (2018) (1)
The J-curve interpreted. An alternative explanation of the results. (1996) (1)
Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML. (2022) (1)
No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs) (2017) (1)
Whole Exome Sequencing to Predict Response to Hypomethylating Agents in MDS (2012) (1)
Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) (2018) (1)
Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS): MDS‐161 (2017) (1)
Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis (2011) (1)
Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry (2018) (1)
Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review (2022) (1)
Mechanisms of Defective Hydroxylation of 5-Methylcytosine in MDS Include Pathways Other Than TET2 and IDH1/2 (2011) (1)
Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid Neoplasms (2022) (1)
What constitutes meaningful improvement in myelodysplastic syndromes? (2022) (1)
Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence (2020) (1)
Is the cure the poison? The evolving story of therapy-related myeloid malignancies (2015) (1)
Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States (2018) (1)
Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. (2015) (1)
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (2021) (1)
Fluoroquinolone Prophylaxis in Acute Myeloid Leukemia (AML) Patients Undergoing Post-Remission Chemotherapy Reduces Hospital Admission Rates (2011) (1)
The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia (2020) (1)
APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis. (2015) (1)
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review (2021) (1)
Treating myelodysplastic syndromes: is more better? (2015) (1)
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria (2019) (1)
Mutation Screening Associated with Chromosome 7 Abnormalities Using Next Generation Whole Exome Sequencing (2012) (1)
Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML (2015) (1)
Hemochromatois-Associated Gene Mutations in Patients with Myelodysplastic Syndromes with Refractory Anemia and Ringed Sideroblasts. (2006) (1)
Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes (2020) (1)
Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC) (2016) (1)
A Specific Mechanism By Which NPM1 mutations Impede Myeloid Differentiation Also Explains The Link With DNMT3A Mutation (2013) (1)
Phase II Randomized Double-Blinded Study of Pracinostat in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes (2017) (1)
Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) (2016) (1)
Treatment Patterns and Survival Outcomes of Patients with Acute Myeloid Leukemia Who Achieved Remission in the Connect ® Myeloid Disease Registry (2021) (1)
Time to Nadir Peripheral White Blood Cell Count (WBC) and Absolute WBC Nadir Value Following Induction Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML) Predicts Survival. (2004) (1)
Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations (2021) (1)
Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms (2021) (1)
New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders (2010) (1)
Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential (2018) (1)
Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome (2017) (1)
c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML. (2006) (1)
The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis (2017) (1)
Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q. (2012) (1)
Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614. (2012) (1)
Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies (2016) (1)
Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML). (2009) (1)
Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors (2019) (1)
Molecular Defects In BRCC3 Complex, a Novel Pathogenic Pathway In MDS (2013) (1)
Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS) (2015) (1)
Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia (2014) (1)
MDS-336: Phase 2 Study of Pevonedistat + Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS (2020) (1)
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study (2019) (1)
Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML (2015) (1)
Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. (2022) (1)
Non-p53 Dependent, Leukemia Initiating-Cell Selective, Therapy. (2009) (1)
The Complete Mutatome and Clonal Architecture of Del(5q) (2015) (1)
Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications (2015) (1)
Germline Events In GFI1 In Myelodysplastic Syndrome (2013) (1)
Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes (2015) (1)
Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy (2011) (1)
Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy (2018) (1)
Inhibition Of JAK-STAT Pathway As a Therapeutic Option For Myelofibrosis Associated Pulmonary Hypertension (2013) (1)
The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies (2014) (1)
A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes (2022) (1)
Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy (2015) (1)
A phase II study with CP-4055 in patients with second salvage AML. (2016) (1)
Spliceosomal Gene LUC7L2 Mutation Causes Missplicing and Alteration Of Gene Expression In Myeloid Neoplasms (2013) (1)
Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms (2016) (1)
Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes (2016) (1)
Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents? (2019) (1)
Molecular Lesions Associated with Loss of Heterozygosity Identified in CMML. (2009) (1)
OlRIGINAL ARTICLE p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia (2011) (1)
Vancomycin-Resistant Enterococcus (VRE) Bacteremia During Acute Myeloid Leukemia (AML) Induction Therapy Is an Independent Predictor of Poor Outcome (2012) (1)
How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS (2019) (1)
LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia (2013) (1)
Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome (2015) (1)
Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium (2013) (1)
Pure Red Cell Aplasia in a Patient with Cri-Du-Chat (2014) (1)
A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS (2016) (1)
A machine learning model of response to hypomethylating agents in myelodysplastic syndromes (2022) (1)
Molecular Characterization of EP300 Mutant Myeloid Neoplasia (2019) (1)
Impact of Day 28 Absolute Lymphocyte Count on Outcome of Adult Patients with Acute Myeloid Leukemia (2014) (1)
Mutation Profiling of Therapy-Related Myeloid Neoplasms Using Next-Generation Sequencing Demonstrates Distinct Profiles from De Novo Disease (2014) (1)
Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis (2022) (1)
High Frequency of Subclonal Myeloid Mutations Can be Found in Large Granular Lymphocyte Leukemia (2017) (1)
Under COVID of the night (2020) (1)
P035 Improvement in cytogenetic diagnosis and clinical prognostication using SNP-A karyotyping in combination with metaphase cytogenetics in MDS, MDS/MPD and secondary AML (2009) (1)
Chromosomal defects Detected by SNP-Array-Based Karyotyping Are Independent Predictors of Survival in Acute Myeloid Leukemia (AML) (2008) (1)
MDS-171: Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial (2020) (1)
A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia (2022) (1)
20 SOMATIC MUTATIONAL MODEL TO PREDICT RESPONSE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES (2015) (1)
An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes. (2022) (1)
Impact of TET2 mutations On Responsiveness to Demethylating Agents in MDS. (2009) (1)
MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS) (2021) (1)
Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia (2012) (1)
A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results (2017) (1)
Novel Pathogenic Defects Of Dead/H-Box Helicases In Myeloid Neoplasms (2013) (1)
Flying without a net in MDS. (2013) (1)
Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology (2021) (1)
Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia (2015) (1)
PF272 GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE (2019) (1)
Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes (2015) (1)
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry (2020) (1)
Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome. (2021) (1)
CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML). (2005) (1)
Comparison of Prognostic Factors and Outcomes of Patients with Secondary Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML). (2007) (1)
PF292 LOW-DOSE CYTARABINE WITH OR WITHOUT GLASDEGIB IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL (2019) (1)
Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (2011) (1)
1123O Evaluation of cell-free DNA approaches for multi-cancer early detection (2021) (1)
Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia (2011) (1)
Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia (2018) (1)
97 CHARACTERISTICS OF ROMIPLOSTIM-TREATED MDS PATIENTS WITH HEMATOLOGIC IMPROVEMENT IN PLATELETS (HI-P) (2015) (1)
Use of SNP-array-based karyotyping for cytogenetic prognostication in unclassified cases of myelodysplasia and associated overlap disorders. (2016) (1)
Distinct Pattern Of Genomic Changes Associated With Smoking In Patients With Myelodysplastic Syndromes (MDS) (2013) (1)
P127 Prospective cross-sectional analysis of cytopenias and transfusion needs of MDS patients in the USA (2007) (1)
Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS) (2011) (1)
RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia (2019) (1)
Array-Based Karyotyping and Genotyping Demonstrates a Non Random Selection of Allelic Variants of Genes in Clones with 5q31 Deletion Mutants (2008) (1)
Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies (2010) (1)
Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37) (2013) (1)
320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM (2015) (1)
A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure (2020) (1)
Somatic Mutational Screen For Improved Prediction Of The Outcomes Of Epigenetic Therapy In MDS (2013) (1)
Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia (2022) (1)
Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes (2013) (1)
DNA Methylation Profiles Capture Clinical and Molecular Heterogeneity of MDS and Can be Harnessed for the Development of Robust Biomarkers Predictive of Response to Azacitidine (2022) (1)
A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine, (2011) (1)
Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis. (2020) (1)
Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay (2018) (1)
TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition (2015) (1)
BCL-2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease (2013) (1)
Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy? (2018) (1)
Prognostic Impact of Molecular Mutations in AML at First Relapse (2015) (1)
Hereditary Mutations Are Present As Pathogenic or Predisposition Factors in Otherwise Typical Adult MDS (2014) (1)
Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence (2020) (1)
Phase I/II Study of Clofarabine Combined with Standard Dose Cytarabine as Remission Induction Therapy of De Novo AML in Elderly Patients ≥60 Years. (2005) (1)
Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) (2017) (1)
Lactate Dehydrogenase (LDH) Level Predicts the Outcome of Patients with Acute Myelogenous Leukemia (AML) Following HLA-Matched Sibling Bone Marrow Transplant (BMT). (2006) (1)
Characteristics of Patients with Myelodysplastic Syndromes (MDS) in the United States from 4528 Physician Surveys. (2007) (1)
Risk Of Acute and Chronic Leukemias Following Radiation Treatment For Locoregional Prostate Cancer In The United States Over 35-Years (2013) (1)
SNP-Array Based Karyotyping Complements Routine Cytogenetics in Diagnosis and Risk Stratification Schemes of MDS (2008) (1)
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. (2015) (1)
Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry (2021) (1)
Chronic Myelomonocytic Leukemia (CMML) Can be Categorized By Ancestral Mutational Events (2014) (0)
Use of single polymorphism arrays (SNP-A) to modify prognostic scoring systems for myelodysplastic syndromes. (2012) (0)
S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP (2019) (0)
66 SUBCLINICAL ANCESTRAL EVENTS FOR PROGRESSION TO MANIFEST CLONAL MYELODYSPLASIA ARE PRESENT IN APLASTIC ANEMIA AT PRESENTATION: COMPARISON OF DE NOVO AND POST AA MDS (2015) (0)
A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure (2015) (0)
Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML. (2010) (0)
O-19 Diagnostic value of array-based CGH in MDS (2005) (0)
Coronavirus and the Cancer Patient (2020) (0)
How flipping burgers can cure leukemia. (2010) (0)
AML-140: Effect of Early Blood Counts on Response and Overall Survival Following Glasdegib Plus LDAC in Newly Diagnosed AML: BRIGHT AML 1003 Post Hoc Analysis (2020) (0)
Preview : Published ahead of advance online publication Distinct clinical and biological implications of various DNMT 3 A mutations in myeloid neoplasms (2017) (0)
A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML) (2012) (0)
Diagnostic Testing Patterns for Ring Sideroblasts (RS) in Patients with Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Connect® MDS/AML Disease Registry (2019) (0)
Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations (2017) (0)
Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes (2015) (0)
International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis (2022) (0)
Tricking or treating myelodysplastic syndromes. (2011) (0)
Predictors of Outcome In Patients with Myelodysplastic Syndromes Living In Western Pennsylvania (2010) (0)
Combination therapies for MDS and AML: Does one plus one equal one? (2016) (0)
Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations (2018) (0)
Characterization, resource use, and the economic impact of low-risk myelodysplastic syndrome (MDS) at an MDS specialty center (2005) (0)
Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML). (2009) (0)
the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes (2016) (0)
Acquired 1p Uniparental Disomy Is Associated with Biallelic MPL W515L Mutation in RARS-T. (2008) (0)
Issue information (2015) (0)
The Relationship between Weekend Admissions and Outcome in Older Adults with Acute Myelogenous Leukemia (AML). (2004) (0)
Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML) (2011) (0)
Immunogenetic Analysis Reveals the Association of INF-γ (+874 A/T) Hypersecretor Genotype in AA and a Low Frequency of KIR-2DL3/C1 Mismatch in Responders to Immunosuppression. (2007) (0)
I-011 Overlap of BMF and MDS (2013) (0)
AML-145: Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients (2020) (0)
Defects of Base Excision Repair Involving OGG1 Can Be Detected in a Subset of Patients with MDS and May Convey Propensity to Chromosomal Breaks. (2006) (0)
Correction: complex landscape of alternative splicing in myeloid neoplasms (2021) (0)
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC) (2017) (0)
Prospective Study Of An Emergency Department Febrile Neutropenia Pathway In Patients With Hematologic Malignancies (2013) (0)
Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms (2022) (0)
Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS (2018) (0)
Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States (2018) (0)
Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms (2016) (0)
Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) (2018) (0)
C021 SNP-array karyotyping complements routine metaphase cytogenetics in the detection of chromosomal aberrations including uniparental disomy in MDS (2007) (0)
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. (2023) (0)
Histone H4 Acetylation Is Associated with Improved Relapse-Free Survival in Newly Diagnosed Patients with Acute Lymphoblastic Leukemia (ALL) Less Than 60 Years of Age without Poor Risk Cytogenetics. (2007) (0)
A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). (2010) (0)
Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) after Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Older Patients with Myeloid Malignancies (2016) (0)
Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia (2018) (0)
60: A high lactate dehydrogenase (LDH) level predicts for shorter survival following HLA-matched sibling bone marrow transplant (BMT) for patients with acute myelogenous leukemia (AML) (2007) (0)
Decitabine therapy in patients with AML or MDS and chromosome 5, 7, or 8 abnormalities. (2010) (0)
Molecular Diversity Detected by Whole Exome Sequencing in Chronic Myelomonocytic Leukemia (2012) (0)
The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure (2014) (0)
BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden (2018) (0)
Risk of hematologic malignancies following radiation treatment for well-differentiated thyroid cancer in the United States over 37 years. (2014) (0)
SNP-A Karyotyping Provides Clinically Relevant Results In Myeloid Hematologic Disorders with Unsuccessful Routine Cytogenetic Testing. (2010) (0)
Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance (2018) (0)
Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations (2013) (0)
A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML) (2016) (0)
Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome (2019) (0)
Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia (2020) (0)
217 DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE (2015) (0)
Estimating Therapy-Related Myeloid Neoplasm Risks in the US (2014) (0)
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (2022) (0)
A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Chronic Idiopathic Myelofibrosis (CIMF) or Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD). (2006) (0)
Triple Negative (JAK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases (2013) (0)
Impact of Weekend Admissions on Quality of Care and Outcomes in Patients with Acute Myeloid Leukemia (AML). (2008) (0)
Patients with SF3B1 Mutation Have Good Prognosis Even in the Presence of Other Poor Prognostic MDS Features and Have Better Outcomes During Treatment with Low Intensity Chemotherapy (2012) (0)
Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial (2022) (0)
Comprar Clinical Malignant Hematology | Mikkael Sekeres | 9780071436502 | Mcgraw-Hill Education (2007) (0)
Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety (2018) (0)
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). (2023) (0)
Mutational Signature and Clonal Architecture of Low Risk Myelodysplastic Syndromes with Del(5Q) (2017) (0)
Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes (2011) (0)
SECOND THOUGHTS FROM SEKERES: Welcoming the I.R.S. to Cancer Clinical Trials (2012) (0)
Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry. (2020) (0)
Abstract IA02: Multicancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay (2020) (0)
Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-Cell Repertoire Responses Otherwise Silenced in Normal Individuals (2016) (0)
TP53 Mutations in Myeloid Neoplasms and Clonal Hematopoiesis of Indeterminate Potential following Cytotoxic Therapy for Antecedent Malignancy: MDS‐305 (2018) (0)
High-Density SNP Arrays Reveals the Possible Presence of Multi-Loci Genetic Predisposition for Myelodysplastic Syndromes (MDS). (2006) (0)
Raising the bar for lower-risk myelodysplastic syndromes. (2023) (0)
Adding Molecular Data to Prognostic Models can Improve their Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS) (2017) (0)
Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) (2018) (0)
The puzzle of cancer recovery. (2014) (0)
MDS: Who Gets It, Diagnosis, and Treatment of Lower-risk (2010) (0)
Disparity in Perceptions of Disease, Treatment Effectiveness and Treatment Adherence Between Physicians and Patients with Myelodysplastic Syndromes (MDS) (2012) (0)
Multiple Mechanisms Leading to ARID2 defects in Myeloid Neoplasms (2014) (0)
Impact of Genetic Polymorphisms on Immune Response and Clinical Features in MDS. (2006) (0)
What my patients taught me about love. (2009) (0)
The Road Less Travelled, from Large Granular Lymphocytic Leukemia to Myelodysplastic Syndrome (2019) (0)
North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia (2015) (0)
page 3947 REVelation ( del : 5 q )---------------------------------------------------------------------------------------------------------------- (2009) (0)
Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML) (2012) (0)
SECOND THOUGHTS FROM SEKERES: How Patient Goals Can Lead to New Cancer Drugs (2013) (0)
Time to Post-Remission Therapy (PRT) Is an Independent Prognostic Factor for Relapse and Overall Survival in Adults with Acute Lymphocytic Leukemia (ALL). (2006) (0)
AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question (2014) (0)
Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions (2016) (0)
Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion (2016) (0)
PR01.08 Simultaneous Multi-Cancer Detection and Tissue of Origin Prediction Via Targeted Bisulfite Sequencing of Plasma Cell-Free DNA (2021) (0)
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia (2020) (0)
MDS-175: Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial (2020) (0)
Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia (2009) (0)
Myelodysplastic Syndromes (MDS) (2018) (0)
Somatic Mutations and Loss-Of-Heterozygosity Impair The DNA Repair Functions Of CUX1 in Myelodysplastic Syndromes (MDS) (2013) (0)
Increased Frequency of Polymorphisms in XRCC3 and OGG1 Genes in Patients with MDS. (2005) (0)
SNP Array Analysis in Refractory Anemia with Ringed Sideroblast Allows for Detection of a High Frequency of Previously Cryptic Chromosomal Defects with Possible Clinical Significance. (2006) (0)
Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance (2017) (0)
Recent Advances in the Treatment of Myelodysplastic Syndromes. Commentary (2009) (0)
AML-156: The Clinical Implications and Outcomes of RAS Mutatome in Core-Binding Factor Acute Myeloid Leukemia (2020) (0)
Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis (2019) (0)
Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions. (2023) (0)
Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics (2010) (0)
Admissions for neutropenic fever in myelodysplastic syndromes (MDS). (2019) (0)
T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience. (2019) (0)
COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study (2021) (0)
Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC). (2006) (0)
249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY (2015) (0)
Encore Abstracts (2007) (0)
Facing cancer : instructions for cancer patients and survivors (2003) (0)
Second Thoughts from Sekeres: A Pyrrhic Victory in the War Against Cancer (2012) (0)
Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS (2019) (0)
A High Resolution Analysis of Chromosome 21 Amplification In Myeloid Malignancies Reveals An Association with a Specific Cytogenetic Subgroup and Enhanced ERG Gene Expression. (2010) (0)
Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS) (2015) (0)
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML) (2019) (0)
Neoadjuvant pertuzumab in early HER2-positive breast cancer. (2013) (0)
Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based Survey (2017) (0)
MDS-120: Molecular and Diagnostic Testing Patterns in Elderly Patients with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry (2020) (0)
Cardiac Screening for Late-Onset Cardiomyopathy in Recipients of Cardiotoxic Chemotherapy: Pilot Data from a Prospective Study (2007) (0)
Waiting for Godot: the true story behind why we need Phase III trials for cancer drugs (2011) (0)
Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia (2018) (0)
166 Safety of panobinostat plus 5-azacitidine in myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia patients: a phase Ib study (2011) (0)
The Revised International Prognostic Scoring System (IPSS-R) Is Not Predictive Of Survival In Patients With Secondary Myelodysplastic Syndromes (MDS) (2013) (0)
Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia (2018) (0)
Meeting Tips: Giving a Scientific Presentation, Being a Good Discussant and Asking a Question in the Aisle (2019) (0)
Acquired Somatic Uniparental Disomy is a Chromosomal Defect Important in Predicting Treatment Responses and Survival Outcomes in MDS, MDS/MPN and Secondary AML (2009) (0)
SECOND THOUGHTS FROM SEKERES: Bold New Colors for Clinical Trials—the New MDS Clinical Research Consortium (2012) (0)
If Nostradamus were treated for MDS. (2011) (0)
Detection of Recurrent Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MDS/MPD-Derived Secondary AML (2007) (0)
Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features (2019) (0)
Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS). (2020) (0)
SECOND THOUGHTS FROM SEKERES: What We Can Still Learn from the Atomic Bomb (2011) (0)
Second Thoughts from Sekeres: Making a Molecular Molehill Out of a Mountain (2011) (0)
The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML) (2015) (0)
Increased CDA expression / activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy Running title : Gender , cytidine deaminase and 5-aza / decitabine (2012) (0)
Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML) (2019) (0)
at Chromosome 7 Carry Distinct Biologic and Prognostic Implications in Myelodysplast ic/Myeloprolifer ative Syndromes and Related Marrow Failures (2000) (0)
A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). (2017) (0)
SECOND THOUGHTS FROM SEKERES: How Good We Have It (2012) (0)
Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments (2013) (0)
P-010 Distinct methylation signature in MDS patients with SF3B1 mutations confers a novel mechanism of disease pathogenesis (2013) (0)
Effect of Early Non-Hematologic Treatment Toxicity on Complete Remission (CR) and Time to CR in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy (2014) (0)
854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN) (2021) (0)
Spliceosome GENE MUTATIONS ARE Also PRESENT In the Diverse Mutational Spectrum of CHRONIC Myelomonocytic LEUKEMIA (2011) (0)
Epsilon aminocaproic acid (EACA) is effective in controlling thrombocytopenic hemorrhage in patients with hematologic malignancies (2005) (0)
Evolving Risk of Myelodysplastic Syndromes Among Adolescents and Young Adults Following Radiation Treatment for First Cancers in the United States, 1973 - 2014 (2016) (0)
P101 Thrombocytopenia in MDS: incidence and impact (2007) (0)
A Psychosocial Assessment of Patients before and after Autologous Stem Cell Transplantation. (2004) (0)
Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004 (2013) (0)
996ORisk of developing acute myeloid leukemia (AML) in well-differentiated thyroid cancer (WDTC) patients treated with radioactive iodine (RAI): a population-based study (2017) (0)
Thirty-year analysis of randomized clinical trials in patients with acute myeloid leukemia. (2016) (0)
Risk Factors for Prolonged Length of Hospitalization in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (2013) (0)
Abstract 5575: Obesity and genomic changes in patients with myelodysplastic syndromes (2015) (0)
Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS) (2011) (0)
Improving Oncology Clinical Trial Accrual (2017) (0)
Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC) (2016) (0)
Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study. (2020) (0)
Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53 (2014) (0)
Clofarabine for myelodysplastic syndromes (2011) (0)
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 (2018) (0)
Octogenarians with AML Can Have Durable Remissions with Venetoclax and Hypomethylating Agent Therapy Despite Significant Dose Reductions (2021) (0)
Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles (2020) (0)
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia (2018) (0)
Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML) (2015) (0)
Time to Complete Remission As a Function of Kinetics of White Blood Cell Elimination and Recovery in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy (2014) (0)
Enasidenib in mutant relapsed or refractory acute myeloid leukemia. (2017) (0)
Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions (2011) (0)
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. (2023) (0)
The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia (2020) (0)
Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub (2021) (0)
Ancestral Events Including Germline and Somatic Mutations Determine Subclonal Events and Affect Phenotype of Progression in MDS (2017) (0)
Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities (2015) (0)
Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes (2022) (0)
Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy. (2008) (0)
Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS) (2020) (0)
Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine. (2010) (0)
Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia (2019) (0)
SECOND THOUGHTS FROM SEKERES: Whatʼs in a Name? (2013) (0)
A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS) (2014) (0)
Defining quality and value in a prospective study of an emergency department (ED) febrile neutropenia pathway (FNP). (2014) (0)
Identifying Immunogenetic Features That Distinguish Immune Mediated, Immunosuppression-Sensitive Disease in Aplastic Anemia (AA) (2012) (0)
PS1029 CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL (2019) (0)
SECOND THOUGHTS FROM SEKERES: Baby Steps or Giant Leaps for Cancer Drug Approval? (2010) (0)
Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype (2018) (0)
Higher Rates of AML Transformation and Poor Risk Cytogenetics in Patients with Low Average Albumin Levels Confers Poor Prognosis in Myelodysplastic Syndromes (2011) (0)
SNP-Array-Based Karyotyping Has Impact on Cytogenetic Diagnosis and Prognosis of Non-Core Binding Factor Primary and Secondary AML. (2007) (0)
TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity (2020) (0)
Use of single nucleotide polymorphism (SNP) array karyotyping to detect clonal chromosomal abnormalities in myelodysplastic syndrome (MDS) and refractory anemia with ringed sideroblasts (RARS) (2008) (0)
The efficacy and safety of darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Results after 53/55 weeks (2006) (0)
MDS-097: Consequences of the Clonal Hierarchy of SF3B1 Mutations on Clinical Phenotypes and Outcomes in Myeloid Neoplasia (2020) (0)
Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS) (2014) (0)
32 Patient-doctor relationship – perceptions (2011) (0)
Eat and be healthy: nutritional status in myelodysplastic syndromes (2020) (0)
Wilms tumor 1 expression: addressing the ‘elephant’ in MDS (2019) (0)
Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia (2012) (0)
Association of Tyrosine Kinase Inhibitors with Vascular Adverse Events: A Cohort Study Using Pooled Electronic Health Record (2017) (0)
Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes (2018) (0)
1031P The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia (2017) (0)
Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q) (2014) (0)
Differences in Iron Distribution in Patients with Myelodysplastic Syndromes Carrying SF3B1 Mutations Using Energy-dispersive X-ray Spectroscopy (XEDS) and Electron-Energy Loss Spectroscopy (EELS) (2013) (0)
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (2021) (0)
Prior Therapy with Rituximab (R) in Patients with Follicular Lymphoma (FL) Does Not Affect Relapse-Free (RFS) or Overall Survival (OS) after High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT). (2006) (0)
The J-curve interpreted (1996) (0)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis (2011) (0)
Attack of the Clones: CHIP in the Clinic (2019) (0)
SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). (2013) (0)
Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation (2018) (0)
Various Abnormalities at Chromosome 7 Carry Distinct Biologic and Prognostic Implications In Myelodysplastic/Myeloproliferative Syndromes and Related Marrow Failures (2010) (0)
Molecular Mutations in U2AF1 Are Most Commonly Found in Del20q Myelodysplastic Syndromes but Do Not Lead to Poor Prognosis in This Karyotypic Subtype (2012) (0)
Histone H4 Acetylation as a Prognostic Factor for Patients with Acute Lymphocytic Leukemia in First Relapse. (2008) (0)
SECOND THOUGHTS FROM SEKERES: Informed Enough… The Limits to Informed Consent (2010) (0)
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort (2018) (0)
Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database (2018) (0)
Characteristics, Mutation Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease (2017) (0)
Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML (2018) (0)
High-Resolution Genomic Arrays Facilitate Detection of Novel Cryptic Chromosomal Lesions in MDS. (2005) (0)
Lower Risk Myelodysplastic Syndrome in Cells Represents a Novel Prognostic Factor Expansion of Effector Memory Regulatory T (2012) (0)
Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) (2018) (0)
SECOND THOUGHTS FROM SEKERES: Polishing Our Crystal Ball (2011) (0)
P-001 Next generation whole exome sequencing for recurrent somatic mutations on chromosome 7 (2013) (0)
Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic (2020) (0)
Clinical and Molecular Features Of Young Patients With Myelodisplastic Syndromes (MDS) (2013) (0)
EZH2 Is Either Mutated or Downregulated in Patients with Loss of Heterozygosity of Chromosome 7/7q and Leads to Epigenetic Dysregulation Via Histone H3K27. (2011) (0)
P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM (2022) (0)
Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure (2017) (0)
Clinical and Molecular Features of FTL3 non Canonical and Activation Loop Mutations (2022) (0)
ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia (2019) (0)
Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium (2014) (0)
Outcomes in Obese and Overweight Acute Myeloid Leukemia (AML) Patients Receiving Chemotherapy Dosed According to Actual Body Weight (2011) (0)
The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes. (2018) (0)
Just and Equitable Enrollment to Pivotal Clinical Trials in Hematologic Malignancies. (2022) (0)
CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q) (2019) (0)
FISH and SNP-Array Karyotyping Improve the Detection of Recurrent Chromosomal Defects Including Del(5q), Monosomy 7, Del(7q), Trisomy 8, and Del(20q) in Myelodysplastic Syndromes. (2008) (0)
Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide (2015) (0)
Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA (2018) (0)
Time, timing, and the treatment of diffuse large B-cell lymphoma (2016) (0)
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q) (2018) (0)
310 RISK OF BONE MARROW FAILURE CONDITIONS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES (2015) (0)
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study (2018) (0)
Impact of Socioeconomic Status and Distance from Treatment Center on Survival in Patients Receiving Remission Induction Therapy for Newly Diagnosed Acute Myelogenous Leukemia (AML). (2006) (0)
The relationship of cigarette smoking to invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy (IC). (2010) (0)
Abstract 5417: Expansion of effector regulatory T-cells represents a novel and independent prognostic factor marking escape from immune surveillance in Myleodysplastic Syndrome (2012) (0)
Lowering the Boom on Lower-Risk MDS (2019) (0)
Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia. (2010) (0)
The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA) (2014) (0)
Ask the Hematologist, September-October 2009 (2009) (0)
Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Registry (2019) (0)
Distinct Features of Chip-Derived and De Novo MDS (2018) (0)
Abstract 5747: Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms (2022) (0)
Clonal Myeloid Events Drive Leukemic Evolution in Antecedent Hematologic Disorders (2019) (0)
‘Henry Kaplan and the Story of Hodgkinʼs Disease’ by Charlotte DeCroes Jacobsʼ (2010) (0)
Chemotherapy and Radiation Results in Distinct Patterns of Somatic Mutations in Subsequent Myeloid Disease (2017) (0)
The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia (2014) (0)
Outcomes for Hispanic Patients with Acute Leukemia Treated at Academic Centers (2021) (0)
Whole Exome Sequencing (“mutatome”) Of Deletion 5q (2013) (0)
SECOND THOUGHTS FROM SEKERES: Gloria Gaynor to the FDA: I Will Survive (2011) (0)
Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations (2016) (0)
Autotransplants for Lymphoid Neoplasms Increase the Risks of MDS More Than AML (2017) (0)
Cytogenetic Classification Systems and Overall Survival Following Bone Marrow Transplant (BMT) for Acute Myelogenous Leukemia (AML). (2005) (0)
Clinical Trial Inclusion of Therapy-Related Myelodysplastic Syndromes (MDS) over the Past 20 Years (2017) (0)
Updating the American Society of Hematology Guidelines for Treating Older Adults with Acute Myeloid Leukemia. (2023) (0)
Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS) (2014) (0)
AML-205: Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib + Azacitidine (2020) (0)
SNP Array Karyotyping Improves Detection Rate of Clonal Chromosomal Abnormalities in Refractory Anemia with Ringed Sideroblasts. (2007) (0)
SECOND THOUGHTS FROM SEKERES: Meta Than Nothing…What to Make of Meta-Analyses of Cancer Risk (2010) (0)
Non-Random Interactions between Founder and Subclonal Mutations Shape the Clinical and Morphological Features of MDS (2017) (0)
Prognostic Impact of Variant Allelic Frequency of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes (2017) (0)
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms (2016) (0)
Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS) (2016) (0)
A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML) (2015) (0)
SECOND THOUGHTS FROM SEKERES: Fever In, Fever Out—Improving Quality in Emergency Room Care of Patients with Fever and Neutropenia (2014) (0)
Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis (2018) (0)
Molecular dissection of normal karyotype acute myeloid leukemia. (2020) (0)
A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF). (2007) (0)
Second Thoughts from Sekeres: Milking the ASCO and ASH Annual Meetings for All Theyʼre Worth (2012) (0)
Baseline predictors of response to treatment with darbepoetin-alpha (DA) in anemic patients with low-risk myelodysplastic syndrome (MDS) (2007) (0)
Journal Pre-proof A machine learning model of response to hypomethylating agents in myelodysplastic syndromes in (2022) (0)
In Response to Lymphohematopoietic Clones (2022) (0)
Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies (2019) (0)
PSY59 Variation in Health-Related Quality of Life Associated With Changes in Transfusion Status of Patients With Myelodysplastic Syndromes Across Six Months of Treatment With Azacitidine (2012) (0)
Functional and Biological Implications of CUX1 Mutations and Deletions in Myeloid Neoplasms (2017) (0)
270 FOUNDER AND SUBCLONAL SOMATIC MUTATIONS CONTRIBUTING TO LEUKEMIC EVOLUTION IN MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS (2015) (0)
A Pilot Application of SELDI-TOF Mass Spectrometry in Bone Marrow Failure Syndromes. (2005) (0)
When Blood Breaks Down (2020) (0)
Parsing the Paradox of Myelodysplastic Syndromes. (2020) (0)
Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012) (2015) (0)
Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation (2019) (0)
BOOKS: ‘YOUR MEDICAL MIND (2013) (0)
TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins (2019) (0)
Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential (2019) (0)
Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS) (2017) (0)
A piece of my mind. The road warriors. (2011) (0)
Assessment of longer-term efficacy, safety, and haematological improvement in the phase 3, randomised, double-blind, placebo-controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions (2020) (0)
O-016 Relationship of different platelet response criteria and patient outcomes in a Romiplostim MDS trial (2013) (0)
Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA) (2015) (0)
67 SUBCLASSIFICATION OF CHRONIC MYELOMONOCYTIC LEUKEMIA BY ANCESTRAL MUTATIONAL EVENTS (2015) (0)
A Phase 1 Trial of Imatinib Mesylate in Combination with Daunorubicin and Cytarabine for Patients for C-kit Positive Relapsed Acute Myeloid Leukemia (AML). (2007) (0)
S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS (2019) (0)
Running Title: SF3B1 and non-MDS and mast cell disease (2013) (0)
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care (2017) (0)
SECOND THOUGHTS FROM SEKERES: Show Me the Money—What Price Clinical Cancer Research? (2013) (0)
MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study (2020) (0)
Drugs and the FDA (2022) (0)
A Quality of Life Assessment of Ablative Allogeneic Bone Marrow Transplant (BMT) Recipients One and Twelve Months after Transplant. (2005) (0)
Large Granular Lymphocytic Leukemia : Common Therapies and their Outcomes (2014) (0)
Differences In Perceptions Of Disease and Treatment Effectiveness and Adherence Between Physicians and Patients With Myelodysplastic Syndromes (MDS) (2013) (0)
UTX mutations in Myeloid Neoplasms (2016) (0)
Use of High Dose Cytarabine (HiDAC) for Post-Remission or Re-Induction Therapy Is Safe and Effective in Select Older AML Patients (2021) (0)
Racial Differences in Prognostic Factors and Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (2012) (0)
SECOND THOUGHTS FROM SEKERES: Waiting for Godot: Why We Need Phase 3 Trials for Cancer Drugs (2010) (0)
Myelodysplastic syndromes. (2022) (0)
Efficacy of Growth Factors Compared to Chemotherapy in Low-Risk Myelodysplastic Syndromes. (2005) (0)
Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS (2017) (0)
Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers? (2018) (0)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes. (2023) (0)
Molecular and Expression Characterization of Monosomy 7 and Del(7q) (2020) (0)
ASH2013: MDS & AML Highlights (2014) (0)
P003 Literature review on the epidemiology of myelodysplastic syndrome (MDS) (2009) (0)
Su1772 MULTI-CANCER DETECTION OF EARLY-STAGE CANCERS WITH SIMULTANEOUS TISSUE LOCALIZATION USING A PLASMA CIRCULATING TUMOR CELL-FREE DNA-BASED TARGETED METHYLATION ASSAY (2020) (0)
Mutational Spectrum of Myelodysplastic Syndrome Malignancies Revealed by Whole Exome Sequencing (2012) (0)
AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT). (2022) (0)
Descriptive comparison of hospital formulary decisions with published oncology valuation methods (2020) (0)
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study (2016) (0)
Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis (2014) (0)
Considerations for Drug Development in Myelodysplastic Syndromes. (2023) (0)
MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program. (2022) (0)
Incidence, Treatment Patterns, and Outcomes of Histiocytic Disorders in the United States: A Forty-Year Population Study (2017) (0)
High Throughput Methylation Arrays Allow for Identification of Complex Methylation Patterns in MDS. (2007) (0)
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes (2022) (0)
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study. (2023) (0)
SF3B1, a Splicing Factor Gene, Is Infrequently Mutated in Rare Bone Marrow Failure Diseases but Still Associated with Ring Sideroblast Phenotype (2012) (0)
Health-related quality of life (HRQoL) in patients (pts) with myelodysplastic syndromes (MDS) in the Connect Myeloid Disease Registry. (2021) (0)
Epsilon Aminocaproic Acid (EACA) Reduces Transfusion Requirements in Patients with Thrombocytopenic Hemorrhage. (2004) (0)
Characterization of the Mutational Spectrum in Young Patients with Myelodysplastic Syndrome (2015) (0)
Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy (2022) (0)
Anemia Associated with Increased IL-6 and IL-8 Levels Predicts for Worse Progression-Free Survival in T-Cell and NK-Cell Large Granular Lymphocyte (LGL) Leukemia but Is Improved by Treatment with Cyclophosphamide (2012) (0)
High-Resolution Genomic Scan for Cryptic Chromosomal Lesions in MDS and AML. (2004) (0)
Whole Genome 250K SNP Array Allows for Detection of Previously Unidentified Lesions in Chromosome 5 in Patients with MDS. (2006) (0)
Race (and ethnicity) matters in myelodysplastic syndromes (2022) (0)
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy (2019) (0)
Influence of type of antecedent disorder on outcome of therapy-related AML. (2011) (0)
401 Distribution and Significance of EZH2 Mutations in MDS and Related Myeloid Malignancies (2011) (0)
Myeloid Cancer Mutation Rates Depend on Prior Cancer Therapies (2017) (0)
MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS) (2020) (0)
Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms (2014) (0)
The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML). (2009) (0)
Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines (2014) (0)
Arsenic trioxide as a treatment for myelodysplastic syndrome. (2005) (0)
A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients (2014) (0)
SECOND THOUGHTS FROM SEKERES: What The Millionaire Matchmaker Teaches Us about Success in Academic Oncology (2011) (0)
Increased Risk of Developing Myeloid Neoplasms, Including Myelodysplastic Syndrome, in Well-Differentiated Thyroid Cancers Treated with Radioactive Iodine (2017) (0)
Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria (2019) (0)
Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study (2022) (0)
with higher-risk myelodysplastic syndromes Phase 2 study of the lenalidomide and azacitidine combination in patients (2013) (0)
Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies (2018) (0)
Disease pathology - Impact of novel and targeted therapies (2009) (0)
Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes (2012) (0)
Cigarette Smoking Is Associated with Increased Rates of Fungal Infection and Increased Mortality After Allogeneic Transplantation (2010) (0)
Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response (2016) (0)
Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia (2017) (0)
Blasts Express Phospho-Akt in the Majority of Adult Patients with Acute Lymphocytic Leukemia (ALL). (2006) (0)
Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes (2018) (0)
Survival and Predictors of Outcome in Acute Leukemia Patients Admitted to the Intensive Care Unit. (2005) (0)
What unique language should you utilise at the present time (2011) (0)
Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications (2019) (0)
Partial Transmission Kidney Blocks to Reduce Radiation Nephropathy in Patients Receiving Myeloablative Total Body Irradiation (2019) (0)
Knowledge That the Myelodysplastic Syndromes (MDS) Are a Type of Cancer Does Not Influence Patient Perception of Treatment Discontinuation (2014) (0)
P-180 Final report of an open-label extension (OLE) study of romiplostim in MDS with a focus on patients with prolonged treatment (2013) (0)
SECOND THOUGHTS FROM SEKERES: ASH 2012—Research That Caught My Attention in MDS and AML (2013) (0)
Targeting Autophagy in Myelodysplastic Syndromes (2016) (0)
Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422. (2008) (0)
progression to AML Aberrant DNA methylation is a dominant mechanism in MDS (2009) (0)
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. (2022) (0)
The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia (2019) (0)
Newly Acquired Molecular Mutations and SNP-A Lesions Alters the Natural History of Trisomy 8 Myeloid Neoplasms (2012) (0)
AML-207: Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence (2020) (0)
Improving clinical trials in higher-risk myelodysplastic syndromes. (2022) (0)
SECOND THOUGHTS FROM SEKERES: On (cology) Language (2011) (0)
Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS) (2018) (0)
Hospital readmission rate for febrile neutropenia (FN) following high dose cytarabine (HiDAC) consolidation chemotherapy for acute myeloid leukemia (AML). (2017) (0)
A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST t (2016) (0)
79 RISK OF MYELODYSPLASTIC SYNDROMES IN WELL-DIFFERENTIATED THYROID CANCERS TREATED WITH RADIOACTIVE IODINE (2015) (0)
33 Optimising combination strategies (2011) (0)
A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML (2010) (0)
Whole Epigenome Pattern Characterization in CMML and Related Monocytoid Malignancies. (2009) (0)
Myelodysplastic/myeloproliferative neoplasm overlap syndromes (2016) (0)
PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777) (2020) (0)
Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents (2017) (0)
The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities, (2011) (0)
A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS. (2006) (0)
Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms (2019) (0)
SECOND THOUGHTS FROM SEKERES: Genomics Matters (2013) (0)
Trying to Remember How We Saw Patients on That April Morning. (2020) (0)
Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Incidence, Risk Factors, and Impact On Survival (2012) (0)
Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS (2018) (0)
Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs) (2014) (0)
Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. (2014) (0)
SECOND THOUGHTS FROM SEKERES: Of God and Cancer (2014) (0)
Reply to H. Kantarjian et al. (2013) (0)
Psychosocial Factors in Decision-Making of Patient Eligibility for Allogeneic Bone Marrow Transplantation. (2004) (0)
88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? (2015) (0)
Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia (2018) (0)
Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function (2019) (0)
Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (LR-MDS) (2017) (0)
TET2 Mutations Are Frequent in RARS-T. (2009) (0)
Overexpression of MPG Is Associated with Distinct Defects in Base Excision Repair in a Subgroup of Patients with MDS. (2006) (0)
TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer (2018) (0)
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories (2022) (0)
Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients (2019) (0)
PSY72 VARIATION BY AGE IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS INITIATING TREATMENT FOR MYELODYSPLASTIC SYNDROMES (2011) (0)
OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia. (2008) (0)
Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). (2021) (0)
SECOND THOUGHTS FROM SEKERES: Another (!!) Letter from a Cleveland Jail to the American Board of Internal Medicine (2013) (0)
Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower-risk myelodysplastic syndromes enrolled in the MEDALIST trial (2020) (0)
Myelodysplastic Syndromes: Going Gently Into That Good Night. (2016) (0)
MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777) (2021) (0)
Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) (2017) (0)
Eligibility Criteria Are Not Associated with Expected or Observed Adverse Events in Randomized Controlled Trials (RCTs) of Hematologic Malignancies (2015) (0)
Germline Variants of RUNX-1 in Myeloid Malignancy (2016) (0)
Erratum: The myelodysplastic syndromes (Expert Opinion on Biological Therapy (2007) 7:3 (369-377)) (2012) (0)
1032PPharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients (2017) (0)
Effective and Non-Cytotoxic p53 Independent Epigenetic-Differentiation Therapy In Xeno-Transplant Models of Human Acute Myeloid Leukemia (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mikkael Aaron Sekeres?

Mikkael Aaron Sekeres is affiliated with the following schools:

University of Amsterdam
University of Oxford
Ewha Womans University
University of California, Los Angeles
University of Chicago
Johns Hopkins University
University of Miami
Karolinska Institute
University of Münster